Boehringer Ingelheim GmbH won approval in the US for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company.

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

According to reports from U.S. CN... Daiichi Sankyo invests 223 billion won in Enhertu production facility in China Japanese pharmaceutical company Daiichi Sankyo, which recorded annual sales of 4 ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

Upon arrival and facing fans at the airport, Son Heung-min and Yang Min-hyeok greeted them happily while unfolding the ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.